<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190120042436N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-01-29</date_registration>
      <primary_sponsor>Yasouj University of Medical Sciences</primary_sponsor>
      <public_title>Comparative study of combined the effect of Cucurbita pepo L. oil and 1% silver sulfadiazine ointment on wound healing and severity of second degree burn pain</public_title>
      <acronym></acronym>
      <scientific_title>Comparative study of combined the effect of Cucurbita pepo L. oil and 1% silver sulfadiazine ointment with the control group on wound healing and severity of second degree burn pain in children 2-7 years</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-02-09</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>98</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/68215</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Eligible children are selected through non-probability (available) sampling, but they are assigned to one of the two groups of intervention exercises and the control group in the form of random block allocation. The random allocation of blocks will be in such a way that according to the number of studied groups, which consists of two groups consisting of group 1 (intervention) and group 2 (control), the number of blocks will be calculated based on the factorial law, that is, 2 = 1 * 2 = 2! . The possible arrangement modes of the participants from each group in each block are indicated by the label A representing group 1 (intervention), B representing group 2 (control). Therefore, there are 2 blocks for random allocation, where there are 2 participants in each block, one person from each group, but their order is different. Block sampling will continue until the number of samples is completed. It should be noted that since there are 2 samples in each block, the number of selected samples will be the same in both groups, Blinding description: In this study, the patients are informed that they may be placed in one of the intervention or control groups, and naturally they will receive the medicine related to the same group. In addition, the main researcher and the nurse who is responsible for the care of the patients, the person responsible for collecting the data and those who evaluate the outcome and the person responsible for the analysis will not know the type of intervention for each person or group.</study_design>
      <phase>3</phase>
      <hc_freetext>Burn of second degree.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The studied patients are dressed with pumpkin seed oil by the researcher once a day for a period of 14 days. The experimental group is treated with pumpkin seed oil. In this way, after washing the wounds daily with normal saline, in second-degree superficial wounds that usually have a complete blister, without removing the blister in the experimental group, a layer of pumpkin seed oil with a diameter of 5 mm will be placed on the wound and It is a dressing. In a second degree deep wound where the blisters are usually destroyed, after removing the blisters and dead tissues and washing the wound surface with normal saline in a sterile way and placing a layer of pumpkin seed oil with a diameter of 5 mm on the wound, a bandage is applied. be made patients in six stages; The first session before the start of treatment, the third day, the seventh day and the day of the clear start of epithelization, the day of recovery and the fourteenth day after the start of treatment are evaluated, and the day of the clear start of epithelization and the start of the repair process will be recorded for each patient. To check the condition of the wound, they are evaluated during the study and every time the dressing is changed. If any of the samples stop participating in the research for some reason, they will be removed and other samples will be selected and replaced in their place. Also, the condition of the wound is checked for the presence of granulation tissue and epithelization every time the dressing is changed. If signs of infection are observed, the sample will be removed from the study and referred to the doctor for further treatment. In order to increase the accuracy and accuracy of the research, two observers (the researcher and the permanent nurse who changes the dressing) will be used before the study and compared in the observed position. In addition, in each session, with the consent of the patient, photographs are taken of the lesions and they are examined in terms of the healing process. In this study, patients, caregivers, researchers and the person responsible for the analysis will not know the type of intervention for each person or group. Intervention 2: Control group: The studied patients were dressed with 1% silver sulfadiazine by the researcher once a day for a period of 14 days. The control group is treated only with 1% silver sulfadiazine. In this way, after washing the wounds daily with normal saline, in second-degree superficial wounds that usually have a complete blister, without removing the blister in the control group, a layer of 1% silver sulfadiazine cream with a diameter of 5 mm will be placed on the wound. And it is bandaged. In a second degree deep wound where the blisters are usually destroyed, after removing the blisters and dead tissues and washing the wound surface with normal saline in a sterile way and placing a layer of pumpkin seed oil with a diameter of 5 mm on the wound, a bandage is applied. be made patients in six stages; The first session before the start of treatment, the third day, the seventh day and the day of the clear start of epithelization, the day of recovery and the fourteenth day after the start of treatment are evaluated, and the day of the clear start of epithelization and the start of the repair process will be recorded for each patient. To check the condition of the wound, they are evaluated during the study and every time the dressing is changed. If any of the samples stop participating in the research for some reason, they will be removed and other samples will be selected and replaced in their place. Also, the condition of the wound is checked for the presence of granulation tissue and epithelization every time the dressing is changed. If signs of infection are observed, the sample will be removed from the study and referred to the doctor for further treatment. In order to increase the accuracy and accuracy of the research, two observers (researcher and a permanent nurse changing the dressing) will be checked and compared before the study, in the observed position. In addition, in each session, with the consent of the patient, photographs are taken of the lesions and they are examined in terms of the healing process. In this study, patients, researchers, nurses and the person responsible for the analysis will not know the type of intervention for each person or group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Part of the data related to the main outcome will be shared

When:
Access to data six months after completion of collection and results

To whom:
Access to data through academic institutions

Conditions:
Research works and references

Where to obtain:
Yasuj University of Medical Science, Faculty of Nursing

How to obtain:
Access after going through the relevant administrative procedures

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohsen Salari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Yasuj, next to Imam Sajjad Hospital,Educational Campus, nursing Faculty</address>
        <city>Yasuj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7591755418</zip>
        <telephone>+98 74 3323 4115</telephone>
        <email>salarimo@yahoo.com</email>
        <affiliation>Yasouj University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hosein Sadeghi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Yasuj, next to Imam Sajjad Hospital, Educational Campus - Faculty of Medicine</address>
        <city>Yasuj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7591755418</zip>
        <telephone>+98 74 3323 0290</telephone>
        <email>doctor.sadeghi@gmail.com</email>
        <affiliation>Yasouj University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The cause of thermal burns
Consent to participate in the study
Age 2 to 7 years
Second degree burn and below 20% and thermal type
Burns in the hands and feet except the fingers
Do not wash excessively with water and detergents
Not having diseases that weaken the immune system
The child's face is healthy and does not suffer from any congenital malformation, especially in the organs and face, and does not have trauma in the organs</inclusion_criteria>
      <agemin>2 years</agemin>
      <agemax>7 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Lack of parental consent
Creating an active infection at the site of the lesion
Use of topical immunosuppressants within four weeks before starting treatment
Local infection
Any vascular disease of the brain, cardiovascular
Patients needing a skin graft for treatment</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T30.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Burn of second degree, body region unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The studied patients are dressed with pumpkin seed oil by the researcher once a day for a period of 14 days. The experimental group is treated with pumpkin seed oil. In this way, after washing the wounds daily with normal saline, in second-degree superficial wounds that usually have a complete blister, without removing the blister in the experimental group, a layer of pumpkin seed oil with a diameter of 5 mm will be placed on the wound and It is a dressing. In a second degree deep wound where the blisters are usually destroyed, after removing the blisters and dead tissues and washing the wound surface with normal saline in a sterile way and placing a layer of pumpkin seed oil with a diameter of 5 mm on the wound, a bandage is applied. be made patients in six stages; The first session before the start of treatment, the third day, the seventh day and the day of the clear start of epithelization, the day of recovery and the fourteenth day after the start of treatment are evaluated, and the day of the clear start of epithelization and the start of the repair process will be recorded for each patient. To check the condition of the wound, they are evaluated during the study and every time the dressing is changed. If any of the samples stop participating in the research for some reason, they will be removed and other samples will be selected and replaced in their place. Also, the condition of the wound is checked for the presence of granulation tissue and epithelization every time the dressing is changed. If signs of infection are observed, the sample will be removed from the study and referred to the doctor for further treatment. In order to increase the accuracy and accuracy of the research, two observers (the researcher and the permanent nurse who changes the dressing) will be used before the study and compared in the observed position. In addition, in each session, with the consent of the patient, photographs are taken of the lesions and they are examined in terms of the healing process. In this study, patients, caregivers, researchers and the person responsible for the analysis will not know the type of intervention for each person or group.</i_keyword>
      <i_keyword>Control group: The studied patients were dressed with 1% silver sulfadiazine by the researcher once a day for a period of 14 days. The control group is treated only with 1% silver sulfadiazine. In this way, after washing the wounds daily with normal saline, in second-degree superficial wounds that usually have a complete blister, without removing the blister in the control group, a layer of 1% silver sulfadiazine cream with a diameter of 5 mm will be placed on the wound. And it is bandaged. In a second degree deep wound where the blisters are usually destroyed, after removing the blisters and dead tissues and washing the wound surface with normal saline in a sterile way and placing a layer of pumpkin seed oil with a diameter of 5 mm on the wound, a bandage is applied. be made patients in six stages; The first session before the start of treatment, the third day, the seventh day and the day of the clear start of epithelization, the day of recovery and the fourteenth day after the start of treatment are evaluated, and the day of the clear start of epithelization and the start of the repair process will be recorded for each patient. To check the condition of the wound, they are evaluated during the study and every time the dressing is changed. If any of the samples stop participating in the research for some reason, they will be removed and other samples will be selected and replaced in their place. Also, the condition of the wound is checked for the presence of granulation tissue and epithelization every time the dressing is changed. If signs of infection are observed, the sample will be removed from the study and referred to the doctor for further treatment. In order to increase the accuracy and accuracy of the research, two observers (researcher and a permanent nurse changing the dressing) will be checked and compared before the study, in the observed position. In addition, in each session, with the consent of the patient, photographs are taken of the lesions and they are examined in terms of the healing process. In this study, patients, researchers, nurses and the person responsible for the analysis will not know the type of intervention for each person or group.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Wound healing score of Bates-Jensen Wound Assessment Tool. Timepoint: The first session before the start of treatment, the third day, the seventh day and the day of the clear start of epithelization, the day of repair and the fourteenth day after the start of treatment. Method of measurement: Bates-Jensen Wound Assessment Tool for healing of burn.</prim_outcome>
      <prim_outcome>Pain severity. Timepoint: The first session before the start of treatment, the third day, the seventh day and the day of the clear start of epithelization, the day of repair and the fourteenth day after the start of treatment. Method of measurement: Face, Legs, Activity, Cry, Consolability scale (FLACC scale).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Pain degeneration. Timepoint: The first session before the start of treatment, the third day, the seventh day and the day of the clear start of epithelization, the day of repair and the fourteenth day after the start of treatment. Method of measurement: Bates-Jensen Wound Assessment Tool.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Yasouj University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-01-04</approval_date>
        <contact_name>Research Ethics Committees of Yasuj University of Medical Science</contact_name>
        <contact_address>Shahid Motahari Blvd., Yasuj,  Kohgiluyeh and Boyer-Ahmad Province Yasuj Kohgilouyeh-va-Boyrahmad Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
